Investigational Drug Information for Ladarixin
✉ Email this page to a colleague
What is the drug development status for Ladarixin?
Ladarixin is an investigational drug.
There have been 8 clinical trials for Ladarixin.
The most recent clinical trial was a Phase 2 trial, which was initiated on December 21st 2020.
The most common disease conditions in clinical trials are Diabetes Mellitus, Type 1, Diabetes Mellitus, and Lung Neoplasms. The leading clinical trial sponsors are Dompé Farmaceutici S.p.A, NYU Langone Health, and [disabled in preview].
There are six US patents protecting this investigational drug and seventy international patents.
Summary for Ladarixin
| US Patents | 6 |
| International Patents | 70 |
| US Patent Applications | 33 |
| WIPO Patent Applications | 23 |
| Japanese Patent Applications | 7 |
| Clinical Trial Progress | Phase 2 (2020-12-21) |
| Vendors | 27 |
Recent Clinical Trials for Ladarixin
| Title | Sponsor | Phase |
|---|---|---|
| Ladarixin With Sotorasib in Advanced NSCLC - Phase II | NYU Langone Health | Phase 2 |
| Ladarixin With Sotorasib in Advanced NSCLC - Phase I | NYU Langone Health | Phase 1 |
| Randomized, Double-blind, Clinical Trial on Ladarixin Adjunctive Therapy to Improve Glycemic Control in Type 1 Diabetes. | Dompé Farmaceutici S.p.A | Phase 2 |
Clinical Trial Summary for Ladarixin
Top disease conditions for Ladarixin
Top clinical trial sponsors for Ladarixin
US Patents for Ladarixin
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Ladarixin | ⤷ Sign Up | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | ⤷ Sign Up |
| Ladarixin | ⤷ Sign Up | Soluble C5aR antagonists | ChemoCentryx, Inc. (Mountain View, CA) | ⤷ Sign Up |
| Ladarixin | ⤷ Sign Up | Method for treating cancer using dual antagonists of CXCR1 and CXCR2 | Syntrix Biosystems Inc. (Auburn, WA) | ⤷ Sign Up |
| Ladarixin | ⤷ Sign Up | Diaryl substituted 5,5-fused ring compounds as C5aR inhibitors | ChemoCentryx, Inc. (Mountain View, CA) | ⤷ Sign Up |
| Ladarixin | ⤷ Sign Up | 2-phenylpropionic acid derivatives and pharmaceutical compositions containing them | ⤷ Sign Up | |
| Ladarixin | ⤷ Sign Up | 2-phenylpropionic acid derivatives and pharmaceutical compositions containing them | ⤷ Sign Up | |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Ladarixin
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Ladarixin | Australia | AU2017261372 | 2036-05-05 | ⤷ Sign Up |
| Ladarixin | Canada | CA3023278 | 2036-05-05 | ⤷ Sign Up |
| Ladarixin | China | CN107847398 | 2036-05-05 | ⤷ Sign Up |
| Ladarixin | European Patent Office | EP3452003 | 2036-05-05 | ⤷ Sign Up |
| Ladarixin | European Patent Office | EP3981392 | 2036-05-05 | ⤷ Sign Up |
| Ladarixin | Hong Kong | HK1249728 | 2036-05-05 | ⤷ Sign Up |
| Ladarixin | Japan | JP2019520866 | 2036-05-05 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
